Omada Health’s analysis reveals that participants in their GLP-1 Enhanced Care Track maintained weight loss 16 weeks after discontinuing GLP-1 medication, contrasting with the 6-7% weight regain typically observed in clinical trials. This program combines GLP-1 medication with lifestyle modification strategies, including diet, exercise, sleep, and stress management. The study stems from Omada’s ANSWERS Initiative, which leverages real-world data to analyze the effectiveness of weight management programs.
This positive data is crucial for employers grappling with the high cost of GLP-1 treatments. Employees often discontinue these medications due to cost and other access barriers, leading to weight regain and diminished return on investment for employers. Omada’s program offers a potential solution by providing ongoing support that helps individuals maintain weight loss even after stopping medication, potentially reducing long-term healthcare costs.
Omada’s analysis, based on 63 participants, showed an average weight change of -0.1% at 16 weeks post-discontinuation. Furthermore, 84% of participants experienced less than 4% weight gain within the same timeframe. This contrasts sharply with the estimated 6-7% weight regain observed in clinical trials without such a comprehensive program. These findings suggest that integrated lifestyle changes are key to sustaining weight loss achieved through medication.
This data strengthens Omada Health’s position as a provider of comprehensive weight management solutions. It offers a compelling value proposition to employers seeking cost-effective strategies to address weight-related health issues and the rising expenses associated with GLP-1 medications. The ability to sustain weight loss after medication discontinuation could significantly impact long-term health outcomes and reduce the financial burden on both employers and individuals. This approach may become increasingly relevant as demand for GLP-1 coverage continues to rise while concerns about long-term cost implications persist.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
